In a recent move that caught the attention of investors, Steven Leonard Chapman, CEO and President of Natera, Inc. (NASDAQ:NTRA), a leader in personalized genetic testing and diagnostics, has sold a significant amount of company stock. The transactions, which took place on March 15 and March 28, 2024, resulted in the sale of company shares totaling over $4.7 million.
The sales were conducted at varying prices, with the range falling between $87.9806 and $90.4158 per share. On March 15, Chapman sold 10,265 shares at an average price of $87.9806, followed by a sale of 20,575 shares at an average price of $88.9708, and another batch of 20,070 shares at an average price of $89.6049. Lastly, on March 28, an additional 2,662 shares were sold at an average price of $90.4158.
It's important to note that these sales were made in accordance with a pre-arranged Rule 10b5-1 trading plan, which allows company insiders to sell shares at predetermined times to avoid any accusations of insider trading. Moreover, the transactions were conducted indirectly through the Chapman Family Trust, for which Steven Chapman serves as a trustee, granting him voting and dispositive power over the shares.
While the CEO has sold a considerable number of shares, it's also worth mentioning that on March 27, Chapman acquired the same number of shares, 5,184, through the vesting of Restricted Stock Units (RSUs). These RSUs represent a right to receive shares of the company's common stock and are part of a four-year vesting plan that began in 2021. However, the acquisition did not have any impact on the total dollar value as the transaction price was set at $0.
The sale of shares by a company's CEO can sometimes be interpreted in various ways by the market and investors. However, the use of a 10b5-1 trading plan often indicates that the transactions were planned in advance and not based on any recent or upcoming undisclosed material information about the company.
Investors and market watchers will likely keep a close eye on Natera's stock performance and any future transactions by company insiders to gauge the confidence level of those at the helm of the company.
InvestingPro Insights
As investors digest the news of CEO Steven Leonard Chapman's recent stock sales, Natera, Inc. (NASDAQ:NTRA) remains a company of interest in the personalized genetic testing and diagnostics market. With a current market capitalization of $11.23 billion, Natera's financial health and stock performance continue to be key factors for investors. According to InvestingPro data, the company has experienced a revenue growth of 31.99% over the last twelve months as of Q4 2023, with a significant quarterly revenue growth of 43.2% in Q4 2023. This suggests a robust upward trend in the company's earnings potential.
Despite not being profitable over the last twelve months, with an adjusted P/E ratio of -25.82, Natera's gross profit margin stands at a healthy 45.52%, indicating that the company maintains a strong ability to generate earnings relative to its revenue. However, it's important to note that the company operates with a moderate level of debt, as highlighted by one of the InvestingPro Tips, which could be a consideration for risk-averse investors.
An InvestingPro Tip that stands out in the context of Chapman's stock sales is that the stock is currently trading near its 52-week high, at 96.59% of that value, with a previous close at $91.46. This may provide some context to the CEO's decision to sell shares at this point in time. Additionally, the stock has seen a large price uptick over the last six months, with a total return of 110.08%, and analysts have revised their earnings upwards for the upcoming period, signaling potential optimism about the company's future performance.
For those looking to delve deeper into Natera's financials and stock performance, InvestingPro offers a wealth of additional tips and real-time metrics. To explore these insights and make informed investment decisions, consider subscribing to InvestingPro using the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With 14 additional tips listed in InvestingPro, investors have access to a comprehensive analysis tool to guide their investment strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.